Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents

Med Eng Phys. 2011 Sep;33(7):805-9. doi: 10.1016/j.medengphy.2010.09.006. Epub 2010 Oct 8.

Abstract

In this work we studied the functional differences between the microcirculation of murine tumours that express only single isoforms of vascular endothelial growth factor-A (VEGF), namely VEGF120 and VEGF188, and the effect of VEGF receptor tyrosine kinase (VEGF-R TK) inhibition on their functional response to the vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P), using measurement of red blood cell (RBC) velocity by a 'keyhole' tracking algorithm. RBC velocities in VEGF188 tumours were unaffected by chronic treatment with a VEGF-R tyrosine kinase inhibitor, SU5416, whereas RBC velocities in VEGF120 tumours were significantly increased compared to control VEGF120 tumours. This effect was accompanied by a reduced tumour vascularisation. Pre-treatment of VEGF120 tumours with SU5416 made them much more resistant to CA-4-P treatment, with a RBC velocity response that was very similar to that of the more mature vasculature of the VEGF188 tumours. This study shows that vascular normalisation following anti-angiogenic treatment with a VEGF-R tyrosine kinase inhibitor reduced the response of a previously sensitive tumour line to CA-4-P.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Blood Vessels / drug effects*
  • Blood Vessels / metabolism
  • Blood Vessels / physiopathology
  • Erythrocytes / drug effects*
  • Erythrocytes / metabolism
  • Erythrocytes / physiology
  • Fluorescent Dyes / metabolism*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Hemodynamics / drug effects*
  • Male
  • Mice
  • Neoplasms / blood supply
  • Neoplasms / metabolism
  • Neoplasms / physiopathology*
  • Protein Isoforms / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Stilbenes / pharmacology*
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Antineoplastic Agents
  • Fluorescent Dyes
  • Protein Isoforms
  • Protein Kinase Inhibitors
  • Stilbenes
  • Vascular Endothelial Growth Factor A
  • vascular endothelial growth factor A, mouse
  • Receptor Protein-Tyrosine Kinases
  • fosbretabulin